Reconnecting

The current page stays visible while onset.to reconnects in the background.

onset.to

← All weeks

Highlights Sep 7 - Sep 13, 2026

new every Sunday

This week brought sharper views of how psychedelics alter brain organization, alongside an FDA account of its evolving development framework. Preclinical findings also opened questions about chemotherapy neuropathy and why some tryptamines produce weaker psychedelic responses.

  1. 01 Davis, Farchione and colleagues present the FDA’s evolving framework for psychedelic drug development in NEJM

    FDA officials detail how public comments and three years of experience have reshaped the agency's psychedelic drug-development framework.

    psychedelicalpha.com · Sep 10, 2026 LSD Policy
  2. 02 2C-B verändert die funktionelle Organisation des Gehirns ähnlich wie Psilocybin, erzeugt aber ein teilweise eigenes Muster

    A controlled 7-Tesla fMRI crossover study finds that 2C-B and psilocybin produce overlapping but distinct brain-dynamics signatures.

    psychedelia-stiftung.de · Sep 9, 2026 Psilocybin Research
  3. 03 Study finds psychedelics and anesthetics produce mirror-image patterns of brain organization linked to conscious states

    Researchers find opposing large-scale brain organization under psychedelics and anesthetic states, offering a model of conscious-state changes.

    michiganmedicine.org · Sep 9, 2026 LSD Research
  4. 04 Psilocybin may prevent chemotherapy nerve pain as LSD, MDMA and psychedelic therapies advance through research and regulation

    Two preventive psilocybin doses protected mice from cisplatin-related nerve damage across six chemotherapy cycles, with a human trial planned.

    themicrodose.substack.com · Sep 11, 2026 LSD Research
  5. 05 Studie zeigt: Starke Serotonintransporter-Hemmung kann psychedelische Reaktionen bestimmter Tryptamine abschwächen

    Mouse and cell data suggest strong serotonin transporter inhibition can dampen 5-HT2A-linked responses to some tryptamines.

    psychedelia-stiftung.de · Sep 10, 2026 Other Research
  6. 06 Psilocybin shows unusually strong anxiety results, yet drug developers largely pursue depression and PTSD instead

    A commentary identifies durable anxiety improvements in cancer trials and asks why developers prioritize depression and PTSD instead.

    behavioralwire.com · Sep 7, 2026 LSD Clinical
  7. 07 The Case That Shook Céu do Mar: A Santo Daime leader’s acquittal exposes disputes over abuse, authority, and institutional reform

    A Santo Daime leader's acquittal exposes unresolved tensions around evidence, authority, accountability, and safety in ayahuasca communities.

    chacruna.net · Sep 10, 2026 LSD Ethics